LanZhou Foci Pharmaceutical Co.,Ltd.

Equities

002644

CNE1000019W4

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
7.78 CNY +1.70% Intraday chart for LanZhou Foci Pharmaceutical Co.,Ltd. +8.51% -20.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lanzhou Foci Pharmaceutical Chairman Resigns MT
Lanzhou Foci Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for the Year 2023 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lanzhou Foci Pharma to Buy 60% Stake in Local Peer for 15.5 Million Yuan MT
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Gansu Provincial State-owned Asset Investment Group Co.,Ltd completed the acquisition of 0.80% stake in LanZhou Foci Pharmaceutical Co.,Ltd. for CNY 39 million. CI
LanZhou Foci Pharmaceutical Co.,Ltd.(XSEC:002644) added to S&P Global BMI Index CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lanzhou Foci Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 15, 2023 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Approves Cash Dividend for 2022 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Announces Final Cash Dividend (Tax Included) for 2022 CI
Gansu Provincial State-owned Asset Investment Group Co.,Ltd made a tender off to acquire a 38.37% stake in LanZhou Foci Pharmaceutical Co.,Ltd. for CNY 1.8 billion. CI
Lanzhou Foci Pharma Appoints CFO MT
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Lanzhou Foci Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on May 27, 2022 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Lanzhou Foci Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2021 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Lanzhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
LanZhou Foci Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend on A Shares for the Year 2020, Payable on July 9, 2021 CI
Lanzhou Foci Pharmaceutical Co.,Ltd. Approves Final Dividend for the Year 2020 CI
Chart LanZhou Foci Pharmaceutical Co.,Ltd.
More charts
LanZhou Foci Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs and large health products. The Company’s main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The Company distributes its products under the brand names Foci, Baolu and Mianshan. The Company is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The Company distributes its products in domestic market and to overseas markets.
More about the company